SEHK:9926Biotechs
Akeso (SEHK:9926) Could Be 41% Undervalued On Phase II Breast Cancer Trial Progress
Akeso (SEHK:9926) has just reached a fresh clinical milestone. The company has dosed the first patient in a Phase II trial of its TROP2/Nectin-4 ADC AK146D1 in combination with ivonescimab for advanced breast cancer.
See our latest analysis for Akeso.
Akeso's latest trial update comes after a mixed period for the stock, with a 7 day share price return of 8.58% and a 30 day share price return of 4.78%, but a 90 day share price return that declined 19.95%. Over longer horizons, total...